Evidence map›Paper›PMID 28740367›Full record

ArticlePatient preference and adherence2017

"Open mesh" or "strictly selected population" recruitment? The experience of the randomized controlled MeMeMe trial.

Mauro Cortellini, Franco Berrino, Patrizia Pasanisi

Registry-linked trialAbstract read
In one paragraph

Article in Patient preference and adherence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02960711. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02960711 phase3completed

Randomized Controlled Trial of Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome

Ran2014Enrolled1,600Registered outcomes2Posted comparisons0ConditionsMetabolic SyndromeArmsLudipress, mg stereate, micronized hydrated silica, talcum, Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mauro CortelliniDepartment of Preventive & Predictive Medicine, Foundation IRCCS National Cancer Institute of Milan, Milan, Italy.
Franco BerrinoDepartment of Preventive & Predictive Medicine, Foundation IRCCS National Cancer Institute of Milan, Milan, Italy.
Patrizia PasanisiDepartment of Preventive & Predictive Medicine, Foundation IRCCS National Cancer Institute of Milan, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among randomized controlled trials (RCTs), trials for primary prevention require large samples and long follow-up to obtain a high-quality outcome; therefore the recruitment process and the drop-out rates largely dictate the adequacy of the results. We are conducting a Phase III trial on persons with metabolic syndrome to test the hypothesis that comprehensive lifestyle changes and/or metformin treatment prevents age-related chronic diseases (the MeMeMe trial, EudraCT number: 2012-005427-32, also registered on ClinicalTrials.gov [NCT02960711]). Here, we briefly analyze and discuss the reasons which may lead to participants dropping out from trials. In our experience, participants may back out of a trial for different reasons. Drug-induced side effects are certainly the most compelling reason. But what are the other reasons, relating to the participants' perception of the progress of the trial which led them to withdraw after randomization? What about the time-dependent drop-out rate in primary prevention trials? The primary outcome of this analysis is the point of drop-out from trial, defined as the time from the randomization date to the withdrawal date. Survival functions were non-parametrically estimated using the product-limit estimator. The curves were statistically compared using the log-rank test (

Indexed as

dropoutsmetabolic syndromemetforminprimary preventionsurvival analysis

Identifiers

PMID28740367
PMCPMC5505681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.